Skip to content
Text “Loti” to 833-962-6682 to join the Loti Labs VIP Group!
Loti Labs Resources Peptides

Pemvidutide Research Profile: Dual GLP-1/Glucagon Agonist Mechanisms

Table of Contents Toggle Pemvidutide: A Dual GLP-1/Glucagon Receptor Agonist The Glucagon Paradox: Why Activate a “Counterregulatory” Hormone Receptor? Mechanism of Action at the Receptor Level Pemvidutide vs. Survodutide: Differentiating Dual and Triple Agonists Open Research Questions Pemvidutide: A Dual GLP-1/Glucagon Receptor Agonist Peptide receptor research includes GLP-1 receptor agonists and dual GIP/GLP-1 agonists such [...]

Pemvidutide: A Dual GLP-1/Glucagon Receptor Agonist

Peptide receptor research includes GLP-1 receptor agonists and dual GIP/GLP-1 agonists such as tirzepatide. Pemvidutide, developed by Altimmune, pairs GLP-1 receptor activity with glucagon receptor activity instead. Its dual-receptor pharmacology is the focus of this profile.

The Glucagon Paradox: Why Activate a “Counterregulatory” Hormone Receptor?

Glucagon and GLP-1 act through distinct receptors with different signaling roles. A dual agonist lets researchers examine both receptor activities within the same experimental framework.

Glucagon receptor activation in hepatocytes stimulates fatty acid oxidation, ketogenesis, and amino acid catabolism.

Glucagon receptor signaling also regulates hepatic glucose metabolism.

Mechanism of Action at the Receptor Level

Pemvidutide is a 30-amino-acid peptide engineered for balanced potency at both the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Its sequence incorporates structural elements from both native GLP-1 and glucagon, with modifications to optimize receptor affinity ratios and extend half-life through albumin binding.

Pemvidutide vs. Survodutide: Differentiating Dual and Triple Agonists

Pemvidutide is one of several multi-receptor peptides studied for receptor pharmacology. Survodutide (Boehringer Ingelheim) is also a GLP-1/glucagon dual agonist, while triple agonists add the GIP receptor as a third target.

Comparing these compounds starts with receptor pharmacology, including relative potency at GLP-1R and GCGR. The assay conditions and measured endpoint matter when interpreting those ratios.

In hepatocyte models, researchers can measure GCGR-linked signaling and lipid metabolism. GLP-1R signaling can be measured separately in cells expressing that receptor.

Open Research Questions

These are the questions driving pemvidutide research forward into 2026 and beyond.

Disclaimer: This content is intended for research purposes only and is not meant to constitute medical advice.

Research-use notice

This educational material discusses laboratory research concepts only. Loti Labs products are intended strictly for research and development use and are not for human consumption.

Ready to explore?

Browse high-purity research materials by format or view the full catalog.